Arcturus Therapeutics anticipates Phase 2 LunairCF study data for ARCT-032 in cystic fibrosis patients unresponsive to existing modulators, expected in the first half of 2025.
Arcturus Therapeutics' Kostaive vaccine receives Japanese regulatory approval for updated JN.1 formulation, expected to generate $85 million in revenue.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.